Savara, Inc. - Common Stock (NQ:SVRA)

6.135 +0.215 (+3.63%)

Streaming Delayed Price Updated: 10:13 AM EDT, Apr 14, 2026 Add to My Watchlist

Price and Volume

Volume	120,938
Open	5.970
Bid (Size)	6.130 (400)
Ask (Size)	6.140 (100)
Prev. Close	5.920
Today's Range	5.940 - 6.135
52wk Range	1.890 - 7.005
Shares Outstanding	114,066,080
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference

Today 8:05 EDT

From Savara Inc.

Via Business Wire

Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

April 07, 2026

From Savara Inc.

Via Business Wire

Performance

YTD	+8.8%	+8.8%
1 Month	+17.3%	+17.3%
3 Month	+6.3%	+6.3%
6 Month	+79.9%	+79.9%
1 Year	+111.6%	+111.6%

More News

Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

March 30, 2026

From Savara Inc.

Via Business Wire

VR Adviser Adds Over 1 Million Savara Shares ↗

March 15, 2026

Via The Motley Fool

Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

March 13, 2026

From Savara Inc.

Via Business Wire

Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

March 06, 2026

From Savara Inc.

Via Business Wire

Savara Announces Participation in 2026 Citizens Life Sciences Conference

March 04, 2026

From Savara Inc.

Via Business Wire

SVRA Stock Rises After Hours As FDA Grants Priority Review For Lung Disorder Therapy ↗

February 20, 2026

Via Stocktwits

Get insights into the top gainers and losers of Friday's after-hours session. ↗

February 20, 2026

Via Chartmill

Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

February 20, 2026

From Savara Inc.

Via Business Wire

Savara Announces New Employment Inducement Grant

February 13, 2026

From Savara Inc.

Via Business Wire

Savara Announces Participation in Upcoming Investor Healthcare Conferences

February 04, 2026

From Savara Inc.

Via Business Wire

Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*

January 27, 2026

From Savara Inc.

Via Business Wire

SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Savara, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

January 24, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

Savara Announces New Employment Inducement Grant

January 16, 2026

From Savara Inc.

Via Business Wire

PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*

January 08, 2026

From Savara Inc.

Via Business Wire

What's going on in today's pre-market session ↗

January 02, 2026

Via Chartmill

Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

December 22, 2025

From Savara Inc.

Via Business Wire

Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

December 17, 2025

From Savara Inc.

Via Business Wire

Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*

December 11, 2025

From Savara Inc.

Via Business Wire

Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System

December 02, 2025

From Savara Inc.

Via Business Wire

Savara Announces Participation in Upcoming Investor Healthcare Conferences

November 20, 2025

From Savara Inc.

Via Business Wire

Savara Reports Third Quarter 2025 Financial Results and Provides Business Update

November 12, 2025

From Savara Inc.

Via Business Wire

SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm

November 10, 2025

From Schall Law

Via GlobeNewswire

Class Action Filed Against Savara Inc. (SVRA) - November 7, 2025 Deadline to Join - Contact Levi & Korsinsky

November 07, 2025

Via NewMediaWire

Frequently Asked Questions

Is Savara, Inc. - Common Stock publicly traded?

Yes, Savara, Inc. - Common Stock is publicly traded.

What exchange does Savara, Inc. - Common Stock trade on?

Savara, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Savara, Inc. - Common Stock?

The ticker symbol for Savara, Inc. - Common Stock is SVRA on the Nasdaq Stock Market

What is the current price of Savara, Inc. - Common Stock?

The current price of Savara, Inc. - Common Stock is 6.135

When was Savara, Inc. - Common Stock last traded?

The last trade of Savara, Inc. - Common Stock was at 04/14/26 10:13 AM ET

What is the market capitalization of Savara, Inc. - Common Stock?

The market capitalization of Savara, Inc. - Common Stock is 699.80M

How many shares of Savara, Inc. - Common Stock are outstanding?

Savara, Inc. - Common Stock has 700M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.